Centessa Pharmaceuticals PLC
NASDAQ:CNTA

Watchlist Manager
Centessa Pharmaceuticals PLC Logo
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Watchlist
Price: 17 USD 1.61% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
Centessa Pharmaceuticals PLC?
Write Note

Intrinsic Value

CNTA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CNTA stock under the Base Case scenario is 2.27 USD. Compared to the current market price of 17 USD, Centessa Pharmaceuticals PLC is Overvalued by 87%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CNTA Intrinsic Value
2.27 USD
Overvaluation 87%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Centessa Pharmaceuticals PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CNTA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CNTA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Centessa Pharmaceuticals PLC

Provide an overview of the primary business activities
of Centessa Pharmaceuticals PLC.

What unique competitive advantages
does Centessa Pharmaceuticals PLC hold over its rivals?

What risks and challenges
does Centessa Pharmaceuticals PLC face in the near future?

Has there been any significant insider trading activity
in Centessa Pharmaceuticals PLC recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Centessa Pharmaceuticals PLC.

Provide P/S
for Centessa Pharmaceuticals PLC.

Provide P/E
for Centessa Pharmaceuticals PLC.

Provide P/OCF
for Centessa Pharmaceuticals PLC.

Provide P/FCFE
for Centessa Pharmaceuticals PLC.

Provide P/B
for Centessa Pharmaceuticals PLC.

Provide EV/S
for Centessa Pharmaceuticals PLC.

Provide EV/GP
for Centessa Pharmaceuticals PLC.

Provide EV/EBITDA
for Centessa Pharmaceuticals PLC.

Provide EV/EBIT
for Centessa Pharmaceuticals PLC.

Provide EV/OCF
for Centessa Pharmaceuticals PLC.

Provide EV/FCFF
for Centessa Pharmaceuticals PLC.

Provide EV/IC
for Centessa Pharmaceuticals PLC.

Show me price targets
for Centessa Pharmaceuticals PLC made by professional analysts.

What are the Revenue projections
for Centessa Pharmaceuticals PLC?

How accurate were the past Revenue estimates
for Centessa Pharmaceuticals PLC?

What are the Net Income projections
for Centessa Pharmaceuticals PLC?

How accurate were the past Net Income estimates
for Centessa Pharmaceuticals PLC?

What are the EPS projections
for Centessa Pharmaceuticals PLC?

How accurate were the past EPS estimates
for Centessa Pharmaceuticals PLC?

What are the EBIT projections
for Centessa Pharmaceuticals PLC?

How accurate were the past EBIT estimates
for Centessa Pharmaceuticals PLC?

Compare the revenue forecasts
for Centessa Pharmaceuticals PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Centessa Pharmaceuticals PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Centessa Pharmaceuticals PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Centessa Pharmaceuticals PLC compared to its peers.

Compare the P/E ratios
of Centessa Pharmaceuticals PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Centessa Pharmaceuticals PLC with its peers.

Analyze the financial leverage
of Centessa Pharmaceuticals PLC compared to its main competitors.

Show all profitability ratios
for Centessa Pharmaceuticals PLC.

Provide ROE
for Centessa Pharmaceuticals PLC.

Provide ROA
for Centessa Pharmaceuticals PLC.

Provide ROIC
for Centessa Pharmaceuticals PLC.

Provide ROCE
for Centessa Pharmaceuticals PLC.

Provide Gross Margin
for Centessa Pharmaceuticals PLC.

Provide Operating Margin
for Centessa Pharmaceuticals PLC.

Provide Net Margin
for Centessa Pharmaceuticals PLC.

Provide FCF Margin
for Centessa Pharmaceuticals PLC.

Show all solvency ratios
for Centessa Pharmaceuticals PLC.

Provide D/E Ratio
for Centessa Pharmaceuticals PLC.

Provide D/A Ratio
for Centessa Pharmaceuticals PLC.

Provide Interest Coverage Ratio
for Centessa Pharmaceuticals PLC.

Provide Altman Z-Score Ratio
for Centessa Pharmaceuticals PLC.

Provide Quick Ratio
for Centessa Pharmaceuticals PLC.

Provide Current Ratio
for Centessa Pharmaceuticals PLC.

Provide Cash Ratio
for Centessa Pharmaceuticals PLC.

What is the historical Revenue growth
over the last 5 years for Centessa Pharmaceuticals PLC?

What is the historical Net Income growth
over the last 5 years for Centessa Pharmaceuticals PLC?

What is the current Free Cash Flow
of Centessa Pharmaceuticals PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Centessa Pharmaceuticals PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Centessa Pharmaceuticals PLC

Current Assets 315.1m
Cash & Short-Term Investments 256.5m
Receivables 39.1m
Other Current Assets 19.4m
Non-Current Assets 45.2m
PP&E 13m
Other Non-Current Assets 32.2m
Current Liabilities 39.4m
Accounts Payable 11.8m
Accrued Liabilities 27.5m
Other Current Liabilities 112k
Non-Current Liabilities 84.6m
Long-Term Debt 75.7m
Other Non-Current Liabilities 8.9m
Efficiency

Earnings Waterfall
Centessa Pharmaceuticals PLC

Revenue
6.9m USD
Operating Expenses
-178.1m USD
Operating Income
-171.3m USD
Other Expenses
20.2m USD
Net Income
-151.1m USD

Free Cash Flow Analysis
Centessa Pharmaceuticals PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CNTA Profitability Score
Profitability Due Diligence

Centessa Pharmaceuticals PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score

Centessa Pharmaceuticals PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

CNTA Solvency Score
Solvency Due Diligence

Centessa Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
50/100
Solvency
Score

Centessa Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CNTA Price Targets Summary
Centessa Pharmaceuticals PLC

Wall Street analysts forecast CNTA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CNTA is 26.67 USD with a low forecast of 19.19 USD and a high forecast of 36.75 USD.

Lowest
Price Target
19.19 USD
13% Upside
Average
Price Target
26.67 USD
57% Upside
Highest
Price Target
36.75 USD
116% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CNTA?

Click here to dive deeper.

Dividends

Centessa Pharmaceuticals PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for CNTA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CNTA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Centessa Pharmaceuticals PLC Logo
Centessa Pharmaceuticals PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

1.9B USD

Dividend Yield

0%

Description

Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company is headquartered in Altrincham, Cheshire and currently employs 90 full-time employees. The company went IPO on 2021-05-28. The firm's asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa's clinical stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The firm's preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The firm's subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.

Contact

CHESHIRE
Altrincham
3Rd Floor, 1 Ashley Road
+447391789784.0
www.centessa.com

IPO

2021-05-28

Employees

90

Officers

CEO & Director
Dr. Saurabh Saha M.D., Ph.D.
Chief Administrative Officer
Dr. David M. Chao Ph.D.
CFO and Principal Financial & Accounting Officer
Mr. John J. Crowley CPA
Chief Technology & Quality Officer
Ms. Tia L. Bush
Senior Vice President of Investor Relations & Corporate Communications
Ms. Kristen K. Sheppard Esq., J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. Iqbal J. Hussain L.L.B.
Show More
Chief People Officer
Ms. Karen M. Anderson
Chief Business Officer
Dr. Gregory M. Weinhoff M.B.A., M.D.
President of the Orexin Program
Dr. Mario Alberto Accardi Ph.D.
Senior Vice President of Development Operations
Ms. April Dovholuk
Show Less

See Also

Discover More
What is the Intrinsic Value of one CNTA stock?

The intrinsic value of one CNTA stock under the Base Case scenario is 2.27 USD.

Is CNTA stock undervalued or overvalued?

Compared to the current market price of 17 USD, Centessa Pharmaceuticals PLC is Overvalued by 87%.

Back to Top